Latest Breaking News On - Pre investigational new drug application - Page 1 : comparemela.com

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEric weisblumColumbia universityDrug administrationUniversity of marylandSilo pharma incAmerican psychiatric associationPre investigational new drug applicationPrivate securities litigation reform actSilo pharmaPsychiatric associationPosttraumatic stress

InvestorNewsBreaks – Silo Pharma Inc (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology

InvestorNewsBreaks – Silo Pharma Inc (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Eric weisblumLos angelesUniversity of marylandDrug administrationSilo pharma incColumbia universitySilo pharmaPre investigational new drug applicationDynamic brand portfolio

Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update

recognized standard clinical outcome assessment. In March: Tiziana announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences , that. | April 26, 2023

United statesPaul spencerHoward weinerSaef izzyWilliama haseltineIrina kofflerTanuja chitnisGabriele cerroneClinical program updatesDrug administrationLifesci advisorsAmerican academy of neurologyAnn romney centerGlobenewswire incTiziana life sciencesPatient population expanded access program

Tiziana Life Sciences Ltd : Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel

United statesSaef izzyGabriele cerroneTanuja chitnisIrina kofflerPaul spencerGood laboratory practicePatient population expanded access programAmerican academy of neurologyLifesci advisorsClinical program updatesProceedings of the national academy sciencesDrug administrationBusiness developmentHarvard medical schoolTiziana life sciences ltd

iTolerance, Inc Completes Pre-IND Meeting with U S FDA for Development Program as a Potential Cure for Type 1 Diabetes Without the Need for Life-long Immunosuppression

MIAMI, FL / ACCESSWIRE / March 1, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy

United statesDennis riedlAnthony japourJenene thomasSusan robertsTolerance inc viewDrug administrationTolerance incPre investigational new drug applicationChief executive officerPrivate securities litigation reform actInc view